Cigna Ventures

At the foundation of each of our investments is a commitment to helping our portfolio companies grow so they can better serve employers of all size. Employers make significant investments to make health care more accessible and easier to navigate. Our portfolio companies bring innovations to market that meet some of employers’ most pressing health care needs, including care navigation, advanced primary care, fertility planning and advanced analytics. Here are some of our current key areas of focus: Drug Management: Prices for drugs – particularly in high-cost categories like oncology, obesity and cell gene therapy – are outpacing inflation. We seek investment opportunities that address drug spend and access, with a specific focus on high-cost drugs or conditions that are highly prevalent in employer-sponsored insurance populations. Data and Analytics: Employers need solutions that make the vast amount of available health care data actionable and tailored to their insured populations. As such, we consider investment opportunities that provide the necessary infrastructure and analytic capabilities to impact administrative efficiency or drive improvements in health care quality and price transparency. Small- and Medium-Sized Business (SMB) Solutions: Rising health care costs place a severe burden on SMBs. In fact, the smallest employers are facing the biggest hikes in premium costs. Employers with just 1-10 employees saw a 12% increase in average family plan premiums in 2022. To help navigate this challenge, we weigh investment opportunities that enable SMBs to provide more affordable, high-quality, and equitable health care to employees through new purchasing and coverage models. Behavioral Health: Fragmented solutions have proven ineffective in addressing the behavioral health needs of patients. To help drive change in this area, we’re considering investment opportunities that approach patient care holistically, with behavioral and medical spend linked to create a comprehensive and unified view of the patient. Women’s Health: Despite deep investments in this area from employers, too many gaps in health and access to care still exist. There are opportunities to solve for the discrete, largely unmet, needs of women in the workforce, including but not limited to maternity, menopause, and comprehensive women’s primary care.

SCOR Ventures is the venture investment arm of SCOR Reinsurance, responsible for both investing in and creating partnerships with startups across the insurtech landscape. Since 2017 we have built a global portfolio across three theses: (1) investing in tech-driven underwriting companies (MGAs, carriers) and distributors, (2) software solutions that benefit SCOR and/or our clients, and (3) companies that help people live healthier lives. Our investment scope includes both investments and commercial (re)insurance relationships with startups. We predominantly invest at late Seed / Series A and are interested in a broad range of B2B and B2B2C solutions across MedTech, wellness, wearables, data platforms, and software / AI platforms. What we’re looking for We invest across three thesis areas: Thesis 1: we invest and partner in the ‘Insurers of the Future’: tech-driven underwriting companies (MGAs, carriers) that offer multiple points of digital and business model differentiation across P&C and L&H. We provide direct access to SCOR expertise and our global network to help portfolio companies scale and/or access (re)insurance capacity. With a proven track record of supporting innovative underwriting propositions across multiple lines of business, we understand product development, program structuring, underwriting, pricing and distribution and thus have the capabilities to optimise partnerships between insurtechs and business partners. We predominantly invest at late Seed / Series A. We are class of business agnostic and have partnered with companies across a broad variety of personal and specialty lines. Thesis 2: we invest and partner in software solutions that benefit SCOR and/or our clients. We provide a broad understanding of the interests and pain points of insurers across the world, and the potential to connect companies with insurers through SCOR’s client services initiatives. We predominantly invest later stage vs. Thesis 1 (typically Series A-B) but have occasional appetite for Seed. We prioritise companies: developing data, tools, and methods for obtaining, understanding, pricing and transferring large portfolios of pre-aggregated risks, high-value individual risks such as energy facilities and construction mega-projects, and MGA/coverholder business delivering economically valuable additional services offering a visible outcome which can be used to boost client management or reduce risks. Focus areas include front-end (e.g., underwriting & pricing) policy administration, modelling, risk analytics, and claims developing platforms where insurance has not previously been embedded / distributed, but where SCOR Ventures sees substantial opportunities to close the global protection gap – e.g., marketplaces, “super apps”, b2b fintech, employee benefits working to solve climate and ESG challenges to support the net zero transition and cut emissions for SCOR and SCOR clients. Focus areas include ESG reporting, climate risk analysis and data, carbon offsetting as a solution, circular economy, diversity, equity, and inclusion (DEI) tech, and supply chain transparency. We also see several opportunities in the green insurance product space including solar production or maintenance guarantees, wind input parametric products, solar physical asset damage, cat-bond / ILS and insuring carbon credit projects. Thesis 3: We invest at the intersection of health and technology and partner with companies that help people live healthier lives, deliver in-force or claims outcome improvements, develop new business or add to SCOR’s Knowledge Center capabilities, and assist our clients to transform their offerings. We predominantly invest at late Seed / Series A and are interested in a broad range of B2B and B2B2C solutions across MedTech, wellness, wearables, data platforms, and software / AI platforms. How we operateIntegrated in the wider SCOR business: Direct access to the entirety of SCOR’s capabilities brings unique added value to our portfolio companies. SCOR’s core business has experts in nearly every country, line of business, and functional area, while SCOR Partners bring a broad range of client services, marketing and product development expertise. Mandate: focused on key markets in North America, EMEA and LATAM, with selective deployment in APAC and Africa. Stage and ownership: We invest Seed to Series B. We typically seek greater than 5% ownership at first investment, which may include a board seat (we have led or co-led half of our investments to date). Our investment is intended to make SCOR a meaningful contributor but leave founders room to manage their cap table. We look for a long-term investment and / or commercial relationship but do not seek a fast exit or to ultimately acquire portfolio companies. Partnership approach: we are active supporters of the companies we work with, assisting with technical input, recruitment, capital optimisation and more. The material growth of many insurtech MGAs and carriers has led to increasing demand for (re)insurance capacity; SCOR is a transparent, long-term partner. Insurtechs in SaaS and services segments, meanwhile, have benefited from SCOR’s long-standing client relationships, while SCOR benefits from bringing knowledge, links, and expertise regarding services with genuine value to our clients. We bring value to our portfolio companies by connecting them with other partner companies, as well as with founders and distribution leads in our network. Why partner with SCOR VenturesWe believe in fewer, deeper relationships over the long term. We are flexible and collaborative in our approach, tailoring a solution to your specific needs, in partnership with other insurers, reinsurers, and investors involved in your company as appropriate. We underwrite most major lines of business and geographies globally. We have a global network including insurance licenses but not a competing retail insurance arm. Insurers are our clients, so working with us does not limit your options to associate with insurers. In selected circumstances, we can offer access to Lloyd’s or SCOR’s insurance licenses in the U.S., Europe, Asia, Brazil, South Africa, and other markets. We look to move quickly with direct access to decision makers, whilst leveraging resources and expertise to ensure our partners can build relationships with the appropriate parts of our organization.

Address the critical bottlenecks in both established and emerging markets that limit access and affordability to novel cancer solutions. Inculcate the tenets of ESG (Environmental, Social and Governance) based investing and measure the progress and impact of our portfolio using the following metrics: E: The ability to optimize differential drug and device pricing based on geography and expand access to promising products early in their lifecycle S: Ability to boost R&D productivity through operational optimization and process transformation G: Promote ethical conduct of business and collaboration while ensuring inclusion & diversity What We DoInvest in US and EU based cancer start-ups who are keen to explore emerging markets or engage in collaborative R&D. Streamline the product-market fit and ensure access to supportive infrastructure and resources. Facilitate their collaborative R&D/commercialization strategy in geographies of interest. How We Do It Accelerate the path to successful commercialization for US and EU based start-ups developing the next generation of oncology solutions by: Reducing costs through infrastructure consolidation and collaborative expertise Expanded access to capital Facilitating rapid market penetration and commercial scaling​

Established in 2019, Seae Ventures, a Boston-based firm, identifies and invests in high-performing early-stage healthcare technology and services companies founded primarily by Women and people who identify as Black, Indigenous and People of Color to generate premium strategic and financial value for its partners. Seae prides itself on a data-driven approach to investing that balances the need for structure with the ability to adapt to ever-changing market conditions. We seek to develop and launch innovative solutions that address the diverse needs of the US population. In addition to evaluating and making equity investments, Seae seeks to convene a strong ecosystem of those who are seeking to drive change.

Pureland Global Venture is a direct investment fund and part of the Pureland Group which targets impact investment deals in the medical technology sector. We are Singapore-based with a focus in APAC, India and the US. The fund deals with early-stage companies who have potential to inject value into the patient care system, save lives and reduce gaps in the supply and demand chains. Since we were established, we have invested in multiple medical sectors in both medical devices and ML-based solutions. MISSION - WHAT WE WANT TO ACHIEVE Established with the goal of giving people access to healthcare and also providing them with clinical choices, our mission is to bring medical solutions and savings to 100 million people around the world. We strongly believe in people who don’t just care about profit and who want to make the world a better place by solving real issues and pushing forward the latest evolution in medical technology. We envision bringing together impactful start-ups, commercial partners, insightful advisors and clinical providers in order to build a sustainable foundation for affordable, accessible and high-quality healthcare. WHY HEALTHCARE? Worldwide healthcare spending is expected to continue to rise at an alarming rate with a slight difference in some countries. Of all the leading factors, life expectancy appears to still be on the rise. By 2050, 1/6 people in the world will be over the age of 65 (16%), an increase from 1/11 in 2019 (9%). The number of people aged over 80 is projected to be 426 million by 2050 according to the United Nations population prospects. As we are entering a smart-health generation, the ecosystem demands more cost-effective solutions and appropriate treatments which can be delivered at the appropriate time and location. Clinicians use technology to give more holistic solutions to an aging population and provide more accurate diagnostics. Care delivery stakeholders use data and communicate more effectively and efficiently. Patients are involved in their own treatment plans and more healthcare access is delivered to people who did not previously have access. Unfortunately, we still face issues such as the increasing cost of healthcare, aging population, limited resources and shortages of healthcare professionals in various parts of the world. In order to combat these problems, government support and spending alone is not enough. We believe that these shortages can be filled by technology, which can be our solution for ensuring sufficient healthcare for future generations. This is also the reason why we are keen on enterprises which can provide solutions to combat these issues and create positive changes in the smart-health era. Founded in Singapore, we hope to be able to leverage the geographical advantage of Asia, and put together growth opportunities for these technologies which will make them accessible globally in the long term. WE SUPPORT START-UPS POST INVESTMENTFOUNDER SUPPORT: Start-ups regularly face critical decision-making as businesses grow from continuous market feedback and unexpected situations. We understand how difficult it can be and we will work together with the founders as a team in order to assist them with scaling their company, whether from networking referrals at the R&D stage, business strategy improvement at the growth stage, or EBITDA optimisation at a later stage. We offer support to founders for the optimisation of team structure as their businesses grow so they can overcome challenges and compete globally. MANUFACTURING SUPPORT: Manufacturing is one of the most crucial aspects of any device company, but it is often where mistakes are made. We advise our companies who experience manufacturing challenges from prototyping to mass production. In order to achieve this, we provide strategic value to our portfolio companies by connecting them to cost-effective manufacturing partners throughout the plastic, PCBA, silicon/rubber and final assembly industries. Our partners are high-mix and low-volume suppliers who understand the challenges of start-ups. Outside of production, we assist companies with lower case costing, set-up and management. GOVERNANCE: Establishing a good corporate culture and necessary internal control will mitigate business losses from major risks and lay the foundations for a company to improve. In a later stage funding cycle, correct corporate governance and internal control are paramount before larger funds buy into the company’s vision and growth story. We have a complete understanding of control and our networks are comprised of global experts in financial knowledge and risk assurance who can work together with our companies. FUNDRAISING: We typically fund companies while they are still young, from their seed to their series A round. Given the heavy research and development nature of medical technology companies, they usually require additional funding in order to boost their business quickly. Post-investment, we will not only collaborate on budgets and milestone adjustments but will more importantly offer assistance with financial modeling and revenue projection. This ensures that companies gain a higher chance of future investment. Finally, we work with other larger funds all over the world who specialise in revenue growth in order to understand their needs when they select their investment targets. EXIT: We seek founders with longer-term goals and a desire to take their companies to global players. Given our evergreen nature and flexible exit strategy, we are well suited to the long operation cycle of healthcare companies. At the same time, we understand and respect that some founders have a shorter term goal of M&A to boost market shares, expand business services or leverage bigger players to scale the company. We are experienced in company buy-out considerations and offer our support to founders as long as the company fits within our investment mandate.